Clinical Trial Update: Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating PF-07081532 and Rybelsus (semaglutide) in people with Type 2 diabetes mellitus and obesity has been terminated. Results were posted o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• PF-07081532
• Rybelsus (semaglutide)

Snippet

Sponsor: Pfizer | Conditions: Diabetes Mellitus, Obesity | Phase 2 | Status: TERMINATED | Results posted: 2024-08-01